Skip to content

Evaluation of an Organized Consultation "Return Home" of Patients With a Cancer (CREDO)

Evaluation of an Organized Consultation "Return Home" of Patients With a Cancer (CREDO)

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02857400
Acronym
CREDO
Enrollment
667
Registered
2016-08-05
Start date
2017-07-21
Completion date
2022-08-30
Last updated
2026-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

METASTATIC CANCER

Brief summary

Prospective, open label, randomized and multicentric study evaluating the efficacy of an organized consultation "return home" compared to a current standard of care in patient hospitalized due to metastatic solid tumor cancer. Subject will be randomized (1:1) as described below : • Arm A (standard) : current standard of care ; connection documentation faxed to GP ( General practitioner) on the day of patient's discharge Arm B (experimental) : CREDO standard of care, organized consultation "return home" between patient, GP DESC (diploma of complementary specialized study) and patient's referent GP

Interventions

connection documentation faxed to GP (General practitioner) on the day of patient's discharge

OTHERCREDO standard of care

organized consultation "return home" between patient, GP DESC (diploma of complementary specialized study) and patient's referent GP

Sponsors

Institut Claudius Regaud
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Age \> or = 18 years old 2. Subject hospitalized in an oncology dedicated center for administration of the first chemotherapy cycle. 3. Subject with metastatic solid tumor whatever the organ 4. subject planned to be discharged home after chemotherapy administration 5. Affiliated to the French social security system. 6. Subjects must provide written informed consent prior to any study-specific procedure or assessment

Exclusion criteria

1. Subject included in another trial evaluating the pathways care 2. Pregnant or breastfeedings women 3. Subject law protected

Design outcomes

Primary

MeasureTime frameDescription
Evaluation of an organized consultation "return home" of patients with a metastatic cancerup to 12 monthsEvaluation of number of non planned consultation and hospitalization compared to current standard of care

Secondary

MeasureTime frameDescription
Comparison of the 2 standard of care (current and CREDO) regarding subject' satisfactionup to 12 monthsphone call , specific question
Comparison of the 2 standard of care (current and CREDO) regarding subject's quality of lifeup to 12 monthsquality of life questionnaire
Identification of the conformity of the standard of care regarding the place of careup to 12 monthsComparison with the initial predefined place of standard of care
To quantify the caregiver burden in the 2 standard of care (current and CREDO)up to 12 monthsZarit Burden Interview
To assess the medical and economic consequences of the 2 standard of care (current and CREDO)up to 12 monthsA cost effectiveness analysis will be performed

Countries

France

Contacts

PRINCIPAL_INVESTIGATORMarie-Eve ROUGE BUGAT, MD

Institut Claudius Regaud

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 15, 2026